{"denoms":[{"counts":[{"groupId":"BG000","value":"59"}],"units":"Participants"}],"groups":[{"description":"Daily oral Everolimus 10 mg/day\n\neverolimus","id":"BG000","title":"Everolimus"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"45.8","upperLimit":"81.3","value":"67"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"45"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"47"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"55"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36"}]}],"title":"Epithelial"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"Mesothelioma, NOS"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Biphasic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Not Reported"}],"paramType":"NUMBER","title":"Histology","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"None"},{"categories":[{"measurements":[{"groupId":"BG000","value":"23"}]}],"title":"Single"},{"categories":[{"measurements":[{"groupId":"BG000","value":"31"}]}],"title":"Multiple"}],"paramType":"NUMBER","title":"Number of Metastatic Sites","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"34"}]}],"title":"1 Regimen"},{"categories":[{"measurements":[{"groupId":"BG000","value":"25"}]}],"title":"2 Regimens"}],"paramType":"NUMBER","title":"Prior Systemic Regimens","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"46"}]}],"title":"1"}],"description":"0: Fully active, able to carry on all pre-disease performance without restriction.\n\n1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work.\n2. Ambulatory and capable of self-care but unable to carry out any work activities; up and about more than 50% of waking hours.\n3. Capable of limited self-care, confined to bed or chair more than 50% of waking hours.\n4. Completely disabled; cannot carry on any self-care; totally confined to bed or chair.","paramType":"NUMBER","title":"Performance Status","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"47"}]}],"title":"< 5%"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"5% - < 10%"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"10% - 20%"}],"paramType":"NUMBER","title":"Weight Loss Last 6 Months","unitOfMeasure":"participants"}],"populationDescription":"Number of patients who were eligible and received treatment and thus analyzable."}